Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2018, Article ID 8961690, 7 pages
https://doi.org/10.1155/2018/8961690
Research Article

Awareness of Pleiotropic and Cardioprotective Effect of Statins in Patients with Coronary Artery Disease

1Department of Cardiology, Mersin University, Faculty of Medicine, Mersin, Turkey
2Department of Cardiology, Mersin City Hospital, Mersin, Turkey
3Department of Cardiology, Tarsus State Hospital, Mersin, Turkey
4Department of Biostatistics, Mersin University, Faculty of Medicine, Mersin, Turkey

Correspondence should be addressed to Bugra Ozkan; moc.oohay@nakzoargub

Received 26 February 2018; Revised 2 May 2018; Accepted 9 May 2018; Published 7 June 2018

Academic Editor: Yoshinari Uehara

Copyright © 2018 Bugra Ozkan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Nichols, N. Townsend, P. Scarborough, and M. Rayner, “Cardiovascular disease in Europe 2014: epidemiological update,” European Heart Journal, vol. 35, no. 42, pp. 2950–2959, 2014. View at Publisher · View at Google Scholar
  2. G. H. Brundtland, “From the World Health Organization: reducing risks to health, promoting healthy life,” The Journal of the American Medical Association, vol. 288, article 1974, no. 16, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. K. C. Ferdinand, “The importance of aggressive lipid management in patients at risk: Evidence from recent clinical trials,” Clinical Cardiology, vol. 27, no. S3, pp. 12–15, 2004. View at Publisher · View at Google Scholar
  4. A. L. Catapano, I. Graham, G. De Backer et al., “2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR),” Atherosclerosis, vol. 253, pp. 281–344, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. Heart Protection Study Collaborative Group, “MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebocontrolled trial,” The Lancet, vol. 360, no. 9326, pp. 7–22, 2002. View at Publisher · View at Google Scholar
  6. Türk Kardiyoloji Derneği’nden Metin Münir’e cevap!. 2011. https://www.medikalakademi.com.tr/turk-kardiyoloji-dernegi-metin-munir/.
  7. S. Stacey, HEALTH: Cholesterol: The big fat lie, plus how to prevent heart disease, 2015.
  8. G. Dincer, Z. Sayın Dincer, A. Demir Alsancak, Y. Alsancak, E. Gümüş, and O. Tekin, “Patient compliance to statin treatment: how effective is the media?” Türkiye Aile Hekimliği Dergisi, vol. 20, no. 1, pp. 23–28, 2016. View at Publisher · View at Google Scholar
  9. P. W. Serruvs, M.-C. Morice, A. P. Kappetein et al., “Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease,” The New England Journal of Medicine, vol. 360, no. 10, pp. 961–972, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. Scandinavian Simvastatin Survival Study Group, “Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival study (4S),” The Lancet, vol. 344, no. 8934, pp. 1383–1389, 1994. View at Publisher · View at Google Scholar · View at Scopus
  11. S. E. Nissen, E. M. Tuzcu, P. Schoenhagen et al., “Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial,” The Journal of the American Medical Association, vol. 291, no. 9, pp. 1071–1080, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. S. E. Nissen, S. J. Nicholls, I. Sipahi et al., “Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial,” The Journal of the American Medical Association, vol. 295, no. 13, pp. 1556–1565, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. S. J. Nicholls, C. M. Ballantyne, P. J. Barter et al., “Effect of two intensive statin regimens on progression of coronary disease,” The New England Journal of Medicine, vol. 365, no. 22, pp. 2078–2087, 2078. View at Google Scholar
  14. G. G. Schwartz, A. G. Olsson, M. D. Ezekowitz et al., “Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes the MIRACL study: A randomized controlled trial,” Journal of the American Medical Association, vol. 285, no. 13, pp. 1711–1718, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. J.-Y. Jang, J.-S. Kim, D.-H. Shin et al., “Favorable effect of optimal lipid-lowering therapy on neointimal tissue characteristics after drug-eluting stent implantation: Qualitative optical coherence tomographic analysis,” Atherosclerosis, vol. 242, no. 2, pp. 553–559, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Kültürsay, “Results of the rosuvastatin studies in Turkey,” Archives of the Turkish Society of Cardiology, vol. 35, no. 1, pp. 24–30, 2007. View at Google Scholar
  17. J. P. Frolkis, G. L. Pearce, V. Nambi, S. Minor, and D. L. Sprecher, “Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice,” American Journal of Medicine, vol. 113, no. 8, pp. 625–629, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. M. H. Davidson, “Differences between clinical trial efficacy and real-world effectiveness,” The American Journal of Managed Care, vol. 12, no. 15, pp. S405–S411, 2006. View at Google Scholar
  19. N. J. Stone, J. Robinson, and A. H. Lichtenstein, “2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,” Circulation, vol. 129, Suppl. 2, no. 25, pp. S1–S45, 2014. View at Publisher · View at Google Scholar
  20. O. Yiginer, N. Ozmen, and F. Ozcelik, “Adherence to statin therapy and LDL cholesterol goal attainment in type 2 diabetics and secondary prevention patients: the role of education and knowledge,” Archives of the Turkish Society of Cardiology, vol. 38, no. 8, pp. 544–550, 2010. View at Google Scholar
  21. A. Baessler, M. Fischer, V. Huf et al., “Failure to achieve recommended LDL cholesterol levels by suboptimal statin therapy relates to elevated cardiac event rates,” International Journal of Cardiology, vol. 101, no. 2, pp. 293–298, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Keskin, “Status of Reaching LDL Goals In Diabetic Patients and Frequency of Statin Treatment Compliance,” Ankara Medical Journal, vol. 12, no. 3, pp. 122-123, 2012. View at Google Scholar
  23. C. Kocas, O. Abaci, B. B. Kocas et al., “The role of media on statin adherence,” International Journal of Cardiology, vol. 201, p. 139, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Bezin, F. Francis, N. V. Nguyen et al., “Impact of a public media event on the use of statins in the French population,” Archives of Cardiovascular Diseases, vol. 110, no. 2, pp. 91–98, 2017. View at Publisher · View at Google Scholar · View at Scopus